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Abstract
Although pituitary adenomas are usually benign, unique trophic mechanisms restraining cell proliferation are unclear. As
GH-secreting adenomas are associated with p53/p21-dependent senescence, we tested mechanisms constraining non-
functioning pituitary adenoma growth. Thirty six gonadotroph-derived non-functioning pituitary adenomas all exhibited
DNA damage, but undetectable p21 expression. However, these adenomas all expressed p16, and .90% abundantly
expressed cytoplasmic clusterin associated with induction of the Cdk inhibitor p15 in 70% of gonadotroph and in 26% of
somatotroph lineage adenomas (p=0.006). Murine LbT2 and aT3 gonadotroph pituitary cells, and aGSU.PTTG transgenic
mice with targeted gonadotroph cell adenomas also abundantly expressed clusterin and exhibited features of oncogene-
induced senescence as evidenced by C/EBPb and C/EBPd induction. In turn, C/EBPs activated the clusterin promoter ,5
fold, and elevated clusterin subsequently elicited p15 and p16 expression, acting to arrest murine gonadotroph cell
proliferation. In contrast, specific clusterin suppression by RNAis enhanced gonadotroph proliferation. FOXL2, a tissue-
specific gonadotroph lineage factor, also induced the clusterin promoter ,3 fold in aT3 pituitary cells. As nine of 12
pituitary carcinomas were devoid of clusterin expression, this protein may limit proliferation of benign adenomatous
pituitary cells. These results point to lineage-specific pathways restricting uncontrolled murine and human pituitary
gonadotroph adenoma cell growth.
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Introduction
Pituitary tumors arise from highly specialized cell types
expressing the respective pituitary polypeptide hormones. Thus,
tumors derived from somatotrophs secrete growth hormone (GH),
lactotrophs, prolactin (PRL), thyrotrophs, thyrotropin (TSH), and
corticotrophs, adrenocorticotropin (ACTH). In contrast, non-
functioning pituitary tumors usually arise from non-secreting cells
of gonadotroph origin [1]. Clinically inapparent pituitary tumors
are identified in 25% of autopsy specimens with a population
prevalence of ,77 cases/10
5. Pituitary tumors are usually benign
neoplasms (adenomas), however, they may also exhibit invasive or
recurrent growth. Rarely encountered malignant pituitary carci-
nomas comprise 0.02% of all pituitary tumors, proliferate rapidly
and show extracranial metastases [2,3,4]. Although most aggres-
sive pituitary adenomas persistently exhibit low mitotic activity [3],
mechanisms underlying these unique growth properties are largely
elusive. We postulate that intrinsic cell-specific trophic properties
as well as the lineage-origin of highly differentiated and specialized
pituitary cells underlies constrained adenoma proliferation.
Cellular senescence is characterized by irreversible proliferative
arrest, while cells remain viable and metabolically active.
Proliferation arrest may occur as a result of age-related telomere
shortening, and also in response to oxidative or genotoxic stress,
DNA damage, aneuploidy or chromosomal instability, as well as
oncogene activation [5,6]. Thus, oncogenic RAS causes stable
proliferative arrest rather than transformation in diploid fibro-
blasts [7]. BRAF in benign skin nevi elicits an initial increased
proliferation followed by DNA stress and cellular senescence [8].
As cellular senescence appears to be bypassed in advanced
malignancies [8,9,10], this antiproliferative mechanism may
represent an initial impediment against oncogenic development
[11]. Senescence is mediated by activation of p53/p21 and other
Cdk inhibitors including p15 and p16 [5]. Oncogene-inuced
senescence is also associated with a senescence-messaging
secretome, enabling senescence responses [11].
Clusterin (CLU), a highly conserved cellular and circulating
protein [12], is also known as apolipoprotein J (ApoJ), sulphated
glycoprotein 2 ( SGP-2), testosterone-repressed prostate message 2
(TRPM-2), or serum protein-40(SP-40). Intracellular clusterin
forms include a partially glycosylated uncleaved pre-secretory
protein, a secretory/intracellular glycosylated a-b chain heterodi-
mer, and a anti-apoptotic nuclear form [13,14]. Nuclear clusterin
is induced in response to DNA damage evoked by chemothera-
peutic agents, and protects some tumorous cells from apoptosis
[15,16]. In contrast, intracellular clusterin was also shown to
inhibit prostate cancer cell proliferation, and clusterin knockout
induced highly aggressive transgenic mouse prostate tumors [17].
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cell proliferation [19,20], promotes experimental skin carcinoma
differentiation [21], and exhibits features of a cellular stress
responder [14].
Pituitary tumor transforming gene (PTTG) induction is a
hallmark of human pituitary tumors [22,23,24]. PTTG was
isolated from pituitary tumor cells [25] and PTTG abundance also
correlates with breast, thyroid, endometrial, esophageal and
colorectal tumor invasiveness [26]. PTTG facilitates cell cycle
progression [22,25] and when over-expressed, causes cell trans-
formation [22] and promotes tumor formation in vivo [27].
Transgenic PTTG over-expression targeted to pituitary gonado-
troph cells results in focal pituitary adenoma formation [28], while
Pttg deletion abrogates murine pituitary tumor development [29].
PTTG is the index mammalian securin [30], and both Pttg
deletion [31] as well as overexpression [27] result in aneuploidy
and chromosomal instability highlighting the requirement for
intracellular securin equilibrium to maintain chromosomal
stability [32,33].
In most human GH-producing pituitary adenomas PTTG
overexpression is associated with DNA damage and p21-
dependent senescence [34], however pathways restraining growth
and transformation of the more commonly encountered non-
functioning pituitary adenomas are not known. We show here that
similar to GH-cell adenomas, tumors arising from the gonado-
troph lineage exhibit high PTTG levels and DNA damage.
However, unlike GH-cell adenomas, p53/p21 senescence markers
are not activated in non-functioning adenomas, which do,
however, selectively express abundant cytoplasmic clusterin. High
clusterin levels restrain cell proliferation by triggering Cdk
inhibitors p15, p16 and p27, while suppression of clusterin
expression enhanced pituitary gonadotroph cell proliferation.
Thus, we identify a novel role for clusterin in enabling pituitary
gonadotroph tumor cell proliferation arrest. FOXL2, a transcrip-
tion factor specifically expressed in pituitary gonadotroph cells
[35] stimulates the clusterin promoter, further highlighting a
differential lineage-specific pathway restricting pituitary cell cycle
progression, acting to buffer non-functioning pituitary adenomas
from unrestrained growth.
Results
DNA damage and senescence markers are induced in
human pituitary adenomas
Immunoreactive PTTG was induced in all 36 gonadotroph cell
adenomas analyzed, but not in normal pituitary tissue (Figure 1A),
confirming previous reports [22,23,24]. Markers of DNA damage
and aneuploidy including cH2A.X foci and phopsphorylated
kinase mutated in ataxia telangiectasia (pATM) [36,37] were not
detected by fluorescent immunohistochemistry in two non-
tumorous human pituitary specimens. In contrast, all of 12 human
pituitary adenomas analyzed (2 GH cell, 10 non-secreting
Figure 1. PTTG and DNA damage in human pituitary adenomas. A) PTTG immunoreactivity (brown signal, both intranuclear and
cytoplasmic)) in non-tumorous pituitary and human pituitary gonadotroph adenomas (T-1,2); B) DNA damage in human pituitary adenoma. Confocal
image of human pituitary adenoma and non-tumorous pituitary tissue specimens labeled with cH2.AX or pATM antibodies (green). Both proteins are
expressed in the nucleus. Specimens here and shown below were counterstained with DNA-specific dye ToPro3 (blue).
doi:10.1371/journal.pone.0017924.g001
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reflecting activated DNA damage signaling (Figure 1B).
We showed earlier that human GH-secreting adenomas, but not
carcinomas, abundantly express intra-nuclear p21, an end-point
inhibitor of cell proliferation in the senescence pathway [29,34]. In
contrast, gonadotroph cell adenomas did not express p21
(Figure 2). However, because these tumors also do not (with
exceedingly rare exceptions) evolve to malignancy, we analyzed
additional pathways restraining pituitary tumor cell proliferation.
p16 and p15 of the ARF/INK Cdk inhibitor family act to restrain
cellular proliferation in response to activated oncogenes [8,10],
and were strongly expressed in gonadotroph adenomas. Seventy
percent of gonadotroph adenomas expressed high levels of p15, as
compared to 26% of GH-secreting adenomas (p=0.006, Table 1).
Thus, both DNA damage pathways and senescence markers were
expressed in gonadotroph cell-derived adenomas (Figure 2).
Clusterin is expressed predominantly in gonadotroph cell
adenomas
As Affymetrix datasets (www.oncomine.org) showed that
clusterin mRNA expression was low in advanced metastatic
cancers [18], we measured clusterin immunofluorescence in non-
tumorous pituitary tissue, and in pituitary adenoma cell types
(Figure 3). Of 4 non-tumorous pituitary tissues, 2 exhibited
intermediate (,50% positivity), while 2 cases exhibited very low
(0–5%) clusterin levels. Only 1 of 17 GH/PRL-secreting
adenomas (6%) expressed high clusterin levels, 3 expressed
moderate levels, while this protein was minimally detectable in
13 such adenomas. In contrast, 33 of 36 (92%) of the more
commonly encountered non-functioning adenomas exhibited
abundant clusterin cytoplasmic immunopositivity. We also ana-
lyzed 12 pituitary carcinomas (9 corticotroph cell and 3 PRL cell ).
None of PRL cell carcinomas express clusterin, only 1 corticotroph
cell carcinoma (8%) showed high clusterin levels, 2 (16%)
exhibited moderate clusterin levels, while clusterin was undetect-
able in 6 corticotroph cell carcinoma samples. Thus, 9 of 12 (76%)
carcinomas did not express clusterin (Figure 3 and Table 1). Three
different adenoma types (GH-, PRL- and gonadotroph) were each
analyzed for co-localization of clusterin with respective pituitary
hormone markers. Moderately expressed clusterin in GH-secreting
adenomas did not co-localize with GH, nor with PRL in PRL cell
adenomas. In contrast, clusterin strongly co-localized with aGSU
in all 3 gonadotroph cell adenomas analyzed (Figure 3B).
aGSU.PTTG mice exhibit features of oncogene-induced
pituitary senescence
We recapitulated human gonadotroph tumors in an in vivo
transgenic murine model of gonadotroph PTTG expression driven
by the aGSU promoter [28]. aGSU.PTTG pituitary glands
express up-regulated gonadotroph PTTG with pituitary hyper-
plasia starting from 4 months of age leading to development of
focal pituitary adenomas expressing LH. Other transgenic lines
also expressed GH and PRL [38]. In accordance with evidence
supporting proto-oncogenic properties of PTTG [26], hyperplastic
pre-tumorous pituitary glands derived from transgenic animals
were shown to already express markers of increased pituitary
proliferation as evidenced by increased BrdU incorporation
(Figure 4A ), and elevated levels of pro-proliferative proteins
including PCNA and E2F1 in vivo (Figure 4B). However, as these
animals developed penetrant pituitary tumors only after 10
months, and these invariably remain small, we tested whether
pituitary PTTG overexpression also affects anti-proliferative
pathways in these transgenic mice.
DNA damage was already evident in pre-tumorous transgenic
pituitary glands overexpressing PTTG as evidenced by enhanced
pituitary cH2A.X and pATM levels, accompanied by induced
Figure 2. Cdk inhibitor expression in human pituitary adenomas. Confocal image of human gonadotroph pituitary adenoma specimens
labeled with p21, p16 or p15 antibodies (green, intranucelar).
doi:10.1371/journal.pone.0017924.g002
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Rad51, as well as tumor suppressors including p19 and p53
(Figure 4C). The Cdk inhibitor p27, a marker of DNA damage
[39], was also induced in pre-tumorous aGSU.PTTG pituitary
glands, as were the cell cycle suppressor proteins p15 and p16
(Figure 4D). Two intracellular forms of pituitary clusterin, a
mature glycosylated ,76 kDa secretory form and ,60 kDA pre-
secretory form were up-regulated in the pretumorous transgenic
pituitary gland (Figure 4D).
These results were confirmed by fluorescent immunostaining.
Although only modest cytoplasmic clusterin, and intra-nuclear
p15 and p16 expression were observed in WT murine pituitary
glands, expression of these 3 proteins was enhanced in the
transgenic pre-tumorous pituitary, and further induced in
aGSU.PTTG pituitary tumors (Figure 4E). Thus, features of
oncogene-induced senescence in the aGSU.PTTG pituitary
included induction of the p19/p53/p27 DNA damage pathway,
and both p15 and p16 Cdk inhibitors [7,40]. In the pre-tumorous
hyperplastic aGSU.PTTG pituitary gland the observed increased
SA-b galactosidase activity supported the presence of cellular
senescence (Figure 4F).
Pttg over-expression in LbT2 cells results in a senescent
phenotype
To recapitulate in vivo effects of pituitary Pttg over-expression, we
transiently transfected murine gonadotroph-derived LbT2 cells
with a plasmid expressing murine Pttg, and also isolated LbT2 cells
stably overexpressing Pttg. As shown in Figure 5, Pttg overexpres-
sion lead to induction of clusterin and p15 in both gonadotroph
cell transfectants, similar to in vivo patterns observed in the
aGSU.PTTG pituitary (Figure 4D).
Clones of stably transfected LbT2 cells sorted and selected for
high PTTG expression, showed lower rates of BrdU incorpora-
tion as compared to control vector-expressing cells, reflecting
decreased proliferation (Figure 5C). These transfectants were
spread-out, and larger in size with giant aneuploid nuclei,
consistent with a senescent phenotype (Figure 5D). High Pttg
expression resulted in decreased apoptosis as detected by TUNEL
assay (Figure 5E), and these cells also exhibited increased SA-b-
galactosidase activity (Figure 5 F,G). Thus, constitutively high
gonadotroph cell Pttg expression resulted in premature cellular
senescence similar to the in vivo pituitary phenotype observed in
aGSU.PTTG mice.
Table 1. p15 and clusterin expression in human pituitary
adenomas.
p15 n (%) Clusterin n (%)
Intensity (%) 0–5 6–50 51–100 0–5 6–50 51–100
Tumor Types nn
GH/PRL 27 16(59) 4(15) 7(26) 17 13(76) 3(18) 1(6)
Gonadotroph 43 8(18) 5(12) 30(70) 36 1(3) 2(6) 33(92)
ACTH 14 2(14) 1(7) 11(79) 10 1(10) 0(0) 9(90)
Carcinoma N/A 12 9(76) 2(16) 1(8)
Normal pituitary 5 1(20) 2(40) 2(40) 4 2(50) 2(50) 0(0)
Protein distribution differences between GH/PRL and gonadotroph tumors,
p=0.0006 for p15, and p=0.0001 for clusterin (Wilcoxon Rank Sum Test).
N/A- not available.
doi:10.1371/journal.pone.0017924.t001
Figure 3. Clusterin in human pituitary adenomas. Confocal image of A) human pituitary adenoma and non-tumorous pituitary tissue
specimens showing clusterin (green) expressed exclusively in the cytoplasm; B) Co-localization of clusterin with GH, PRL and aGSU in respective
human pituitary adenoma specimens (clusterin green, respective hormones red).
doi:10.1371/journal.pone.0017924.g003
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C/EBP transcription factors are involved in cellular prolifera-
tion and differentiation [41,42,43]. In the pre-tumorous hyper-
plastic aGSU.PTTG pituitary, C/EBPb was induced both in
aGSU, and in GH- and PRL-secreting cells (Figure 6A). In LbT2
cells stably expressing Pttg, several C/EBPb and C/EBPd isoforms
[41] ) were also up-regulated (Figure 6 B).
We therefore assessed whether C/EBPs activate the clusterin
promoter in LbT2 cells, and also in a murine gonadotroph-derived
aT3 cell line. pGL3-mClu-luc reporter plasmid co-transfected with
full length murine C/EBPb or with C/EBPd constructs (Figure 6C)
resulted in induced luciferase activity in both cell types. However,
the plasmid encoding C/EBPa did not induce the clusterin
promoter, indicating the specificity of C/EBPb and d effects.
Accordingly, clusterin protein levels were also found to be up-
regulated in cells transfected with pcDNA3-C/EBPb and d
respectively (Figure 6 D,E).
As LbT2 mPttg cells exhibit increased clusterin levels, we treated
these cells with siRNAs directed against either C/EBPb or C/
EBPd. However, separate suppression of either of these genes
resulted in compensatory increase of the other protein (data not
shown), while simultaneous suppression of C/EBPb and d with
3 nM of each RNAi lead to decreased clusterin protein levels in
LbT2 mPttg cells after 48 hours. These experiments were
conducted with two different siRNA combinations directed against
both C/EBPb and d, and a representative Western blot is shown
in Figure 6F. The results confirmed that both C/EBP proteins act
to regulate gonadotroph cell clusterin expression.
Clusterin restrains pituitary cell proliferation
As high clusterin expression was observed in benign gonado-
troph adenomas and in small slow-growing aGSU.PTTG pituitary
tumors (Figures 3 and 4E), and also in LbT2 cells overexpressing
mPttg (Figure 5A,B), we analyzed the effects of altering
intracellular clusterin levels. Transient transfection with mClu-
pIRES2-ZsGreen1 resulted in increased p15, p16, and p27
expression in LbT2, and p16 in the aT3 cell line. In contrast,
levels of phosphorylated histone H3 (pH 3), a specific marker for S
and M phases were attenuated in both cell types after clusterin
transfection (Figure 7A,B).
Senescence-associated heterochromatic foci (SAHF) mark
concentrated spots of transcriptionally silenced DNA [44]. This
Figure 4. Pituitary proliferation, DNA damage and senescence markers in the aGSU.PTTG pituitary gland. A) In vivo BrdU incorporation.
Mice were injected with BrdU (50 mg/g BW), and pituitary sections stained for BrdU. One thousand cells/section, 3 sections/animal, n=3 animals/
genotype were analyzed. *, p,0.05; Western blot analysis of B) proliferation markers; C) DNA damage, DNA repair and p53-dependent senescence
markers, and D) oncogene-induced senescence markers; E) Confocal image showing immunofluorescent cytoplasmic clusterin, and intranuclear p15
and p16 expression (green) in WT and in pre-tumorous aGSU.PTTG pituitary glands, and in aGSU.PTTG pituitary adenomas; F) Pituitary SA-b-
galactosidase enzymatic activity (blue) in WT and in pre-tumorous aGSU.PTTG pituitary gland. Three pituitary cryosections/animal were analyzed from
3 animals/genotype, and a representative image shown. Western blots here and elsewhere were repeated 3 times with similar results and
representative blots shown.
doi:10.1371/journal.pone.0017924.g004
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heterochromatin-associated modified histone. Methylation of
lysine 9 of histone H3 (K9M-H3) [8,44] is associated with restraint
of cellular proliferation [44]. Using a specific antibody in LbT2
cells transiently transfected with mClu, we observed 30% increase
in H3-K9M-positive cells (Figure 7 C,D), concordant with
decreased murine gonadotroph cell proliferation observed when
clusterin was overexpressed (Figure 7E).
After synchronization of aT3 cells stably overexpressing mClu,
and adding 10% FBS, cells were pulsed with BrdU, and flow
cytometry demonstrated that BrdU incorporation was decreased,
reflecting attenuated DNA synthesis (Figure 7F).
Next we suppressed clusterin expression in LbT2 mPttg stable
transfectants, and also tested aT3 cells, where endogenous clusterin
levels were relatively high. Both cell lines were transfected with
6 nM of two different siRNAs directed against clusterin, and the
pRS shClu-GFP RNA expressing plasmid. Treatments with
siClu#2 and transfection with shClu-GFP both depleted clusterin
mRNA by 80% as measured by real time PCR (data not shown).
Figure 8 (A,B) shows Western blots of representative experiments
using siClu#2 where both clusterin protein forms were down-
regulated, p15 and p16 levels were low, and pH 3 protein levels
induced in both cell lines. In LbT2mPttg cells and in aT3 cells,
clusterin suppression led to increased numbers of cells incorporating
BrdU respectively (p,0.05) (Figure 8C). Depletion of clusterin by
shClu RNA resulted in 30 and 26% increase in BrdU-positive
LbT2mPttg cells and aT3 cells respectively (data not shown).
The results show that in pituitary gonadotroph cells, induced
clusterin restrains proliferation associated with up-regulated p15
and p16, while clusterin depletion led to decreased p15 and p16,
accompanied by increased cell proliferation. Indeed, suppression
of p15 and p16 transcription by respective siRNAs markedly
increased the number of BrdU-incorporated LbT2mPttg cells
48 hours after transfection, reflective of increased cell proliferation
(Figure 8 D,E).
FOXL2 activates clusterin promoter in gonadotroph
pituitary cells
Forkhead box gene transcription factor L2 (FOXL2) is a cell-
specific factor for pituitary gonadotroph differentiation and
triggers aGSU expression [35]. FOXL2 is abundantly expressed
in human pituitary gonadotroph and null cell adenomas [45], and
in normal pituitary co-localizes with LH, FSH and aGSU [35]. As
distribution of FOXL2 appeared to mirror clusterin expression in
pituitary adenomas, we tested whether FOXL2 stimulates
clusterin in gonadotroph cells. pGL3-mClu-luc reporter plasmid
was co-transfected with the murine FOXL2 (pcDNA3-His-Foxl2)
in aT3 cells (Figure 9A), and luciferase activity was induced,3
fold (p,0.01) indicating the stimulatory effect of FOXL2 on the
clusterin promoter. Clusterin protein levels were also enhanced in
cells transfected with pcDNA3-His-Foxl2 (Figure 9B). In contrast,
clusterin was not induced in ACTH-secreting AtT20 murine
corticotroph pituitary cells transfected with pcDNA3-His-Foxl2
(data not shown), indicating cell specificity of FOXL2 action on
the clusterin promoter.
We then tested whether FOXL2 is recruited to the endogenous
clusterin promoter. Lysates derived from aT3 pituitary gonado-
trophs were isolated and chromatin immunoprecipitation (ChiP)
Figure 5. Senescence markers in gonadotroph-derived LbT2 cells transfected with mPttg. Western blot analysis of senescence markers in
A)L bT2 cells transiently transfected with mPttg; B)i nL bT2 cells stably transfected with mPttg; C) Percent BrdU positive cells in two selected clones
stably transfected with mPttg. Duplicate samples were pulsed with BrdU for 30 min and analyzed by flow cytometry; D) Senescent morphology of
LbT2 cells stably transfected with mPttg. Brown dots depict incorporated BrdU; E) Percent apoptotic cells stably transfected with mPttg. Cells were
fixed, and one thousand cells/field counted in three randomly chosen visual fields; F) Percent SA-b-galactosidase positivity in cells stably transfected
with Pttg was assessed in 6-well plates in triplicate. One thousand cells/field were counted in three fields/well. G) SA-b-galactosidase enzymatic
activity (blue) in cells stably transfected with mPttg.* ,p ,0.05.
doi:10.1371/journal.pone.0017924.g005
Lineage-Specific Restrain of Pituitary Adenomas
PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e17924assays performed with a polyclonal FOXL2 antibody. FOXL2 was
shown to bind the clusterin promoter, spanning 2700–1339
nucleotides upstream from the transcription start site (Figure 9C),
but did not bind the 21468–1865 or +1–700 promoter regions
(not shown). Enrichment of specific 2700–1339 clusterin promot-
er sequences in the precipitate indicated FOXL2 association with
the clusterin promoter in vivo.
Discussion
Pituitary lineage specificity determines highly distinct peripheral
pituitarytrophichormoneactionsasexemplifiedbydifferentiatedGH,
PRL, ACTH, TSH or gonadotroph hormone functions. Cell-specific
pituitary hormone synthesis is regulated by specific hypothalamic,
intrapituitary and peripheral hormone signals [46,47,48,49,50].
Pituitary cells are also sensitive to aneuploidy, DNA damage or
oncogene overexpression. In response to these insults, we show here
thatcell-typespecifictrophicpathwaysareactivated,withthecommon
end-point of pituitary cell proliferation arrest.
GH secreting tumors exhibit high PTTG, features of aneuplody,
chromosomal instability, activation of DNA damage responses,
p21-dependent cell proliferation restraint and senescence [34].
Although high PTTG levels are also observed in gonadotroph
pituitary adenomas [26], unlike GH-cell adenomas, we now show
that gonadotroph adenomas do not express p21, but abundantly
express clusterin in a cell specific manner. In contrast, only modest
clusterin expression was observed in non-tumorous pituitary
glands and in GH/PRL- secreting tumors, while clusterin was
undetectable in 76% of the very rarely encountered pituitary
carcinomas.
The results in human tumors were validated using in vivo and in
vitro models of gonadotroph cell adenomas with high PTTG
expression. Reflecting pro-proliferative properties of excess
PTTG, aGSU.PTTG pituitary glands exhibit microadenoma
formation [38], also evidenced by increased in vivo pituitary BrdU
incorporation, and up-regulated proliferation markers including
PCNA and E2F1. Similar to human pituitary adenomas, in the
aGSU.PTTG pituitary gland, high PTTG levels result in
aneuplody and chromosomal instability, also evidenced by DNA
damage, pATM induction and activation of p53/p27 pathways
known to arrest cell proliferation in the course of continuing DNA
damage [39]. Concordantly, both the pre-tumorous aGSU.PTTG
Figure 6. C/EBPs induce clusterin. A) C/EBPb is up-regulated in the aGSU.PTTG pituitary. Confocal image showing C/EBPb co-localization with
aGSU-positive, GH-positive and PRL-positive cells in WT and pre-tumorous aGSU.PTTG pituitary glands. (Hormones-green, cytoplsmic, C/EBPb–red,
intranuclear); B) Western blot analysis of C/EBPb and d isoforms induced in LbT2 cells stably transfected with mPttg; C) Effects of C/EBPs on the
clusterin promoter in LbT2 and aT3 cells 24 h after transfection. Cells were co-transfected with 200 ng murine pGL3-luc-mClu reporter plasmid and
800 ng murine pCDNA3-C/EBPa, b or d. The ratio of luciferase to co-trasfected b-galactosidase control reporter vector was normalized to pCDNA3-
null expression vector. SEM was calculated from triplicate assays, and experiments repeated three times with similar results. Results of a
representative experiment are shown.*, p,0.05, **,p,0.01; D) Western blot analysis of clusterin expression in gonadotroph-derived aT3 cells
24 hours after transfection with pCDNA3-C/EBPb or E) pCDNA3-C/EBPd; F) Western blot analysis of clusterin expression in LbT2 mPttg cells 48 hours
after simultaneous transfection with siC/EBPb and siC/EBPd (3 nM each). Two different combinations of siRNAs were used.
doi:10.1371/journal.pone.0017924.g006
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clusterin, p15 and p16.
The results suggest a biphasic response to transforming effects of
excess PTTG in vivo: Abundant PTTG is apparently sufficient to
trigger an initial proliferative burst leading to hyperplasia and
tumor initiation, however, inability of these pituitary tumors to
undergo persistent further growth, is likely due to proliferation-
restraining pathways activated by PTTG overexpression. These
finding underscore the observed SA-b-galactosidase activation in
pre-tumorous aGSU.PTTG glands and in LbT2 cells constitutively
expressing Pttg.
High clusterin levels were observed in the aGSU.PTTG
pituitary gland and in LbT2 cells stably and transiently transfected
with mPttg, suggesting that in human gonadotroph adenomas
clusterin might be also induced by high PTTG levels. In
gonadotroph cells, PTTG-overexpression is accompanied by C/
EBP induction. C/EBP proteins uniquely regulate cell-type
specific growth and differentiation [41,42]. C/EBPb is associated
with oncogene-induced senescence [51], while C/EBPd triggers
growth arrest and cell differentiation [43,52,53]. Both C/EBPb
and C/EBPd are shown here to activate the clusterin promoter,
and induced clusterin protein expression was evident in gonado-
troph cells and pituitary tissue overexpressing PTTG. Further-
more, a specific gonadotroph cell lineage transcription factor
FOXL2, independently activates the clusterin promoter in these
cells.
We show that forced clusterin expression in LbT2 and aT3
pituitary gonadotroph cells triggers a linage-specific cytostatic
response, inducing p15, p16, or p27; decreased cell proliferation
was also evidenced by lower expression of pH 3, similar to
observations in prostate cancer cells [54]. Accordingly, when
either p15 or p16 gene expression were suppressed, pituitary cell
proliferation was enhanced. These results are in accordance with
those showing that TGFb-induced p15 decreases proliferation and
induces cell cycle arrest in rat GH3 pituitary cells [55]. Thus,
clusterin-triggered p15 and p16 likely restrain pituitary cell
proliferation in aGSU.PTTG pituitary tumors and in LbT2
gonadotroph-derived cells. Induced p15 in human gonadotroph
adenomas might therefore limit growth of these tumors.
Custerin function in tumorigenesis is unclear. Clusterin
expression is enhanced in human prostate cancer, and antisense
oligonucleotides targeting clusterin inhibit prostate tumorigenesis
Figure 7. Clusterin restrains pituitary cell proliferation by inducing Cdk inhibitors. Western blot analysis of Cdk inhibitors and proliferation
markers A)i nL bT2 cells, B)i naT3 cells 48 h after transfection with mClu; C) Confocal images of immunofluoprescence of histone H3 methylation on
lysine 9 (H3-K9M) (red) in vector and Clu-expressing aT3 cells 48 hours after transfection; D) Quantification of positive H3-K9M foci. Cells were fixed,
stained with H3-K9M antibody, and one thousand cells/field counted in three randomly chosen visual fields; E) Percentage of BrdU positive cells 48 h
after transfection with mClu. Triplicate samples were pulsed with BrdU for 30 min and analyzed by flow cytometry, *, p,0.05; F) aT3 cells stably
overexpressing mClu or vector were synchronized in 0.1% fetal bovine serum for 18 hours, and then cultured in 10% fetal bovine serum. At the
indicated times, duplicate samples were pulsed with BrdU for 30 min, analyzed by flow cytometry, and cells in S-phase identified by staining with
BrdU antibodies.
doi:10.1371/journal.pone.0017924.g007
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metastatic progression [57] and is associated with human lung
adenocarcinoma cell growth [58]. The nuclear anti-apoptotic form
of clusterin is induced in late stage cancers following chemother-
apy, hormonal ablation or radiotherapy, thus protecting tumor
cells undergoing damaging stress [59]. As pituitary carcinomas are
rarely treated with radiation or chemotherapy before surgery, we
did not observe clusterin expression in human carcinoma
specimens, as expected. Several lines of evidence also point to
the role of clusterin as a tumor suppressor protein. Thus, clusterin
was down-regulated, and its expression inversely proportional to
tumor grade/or metastatic stage [16,18,60]. Patients with
clusterin-positive lung cancer have enhanced disease-free survival
[61]. Moreover, Clu
2/2 mice are more prone to oncogene-
induced tumorigenesis [17,21]. Although clusterin restrains
proliferation of untransformed epithelial cells [21] and acts
primarily as a tumor-suppressor during early stages of carcino-
genesis [16,21], when re-expressed in advanced cancers, clusterin
might promote tumor growth.
Based on the results presented here, we propose that in benign
pituitary tumor cells of gonadotroph origin, the role of clusterin is
to restrain proliferation. Similar affects were demonstrated for
TGFb1, which functions as a tumor suppressor in normal
epithelial cells and during early stages of tumor development
[62]. In late-stage tumors TGFb1 exhibits features of a tumor
promoter, modulating vascular and immune compartments of the
tumor stroma [63]. Similarly, in normal fibroblasts [32] and in
benign pituitary tumor cells (here and [34]), high PTTG restrains
the cell cycle and leads to senescence. In transformed tumor cell
lines and in malignant tumors, overexpressed PTTG triggers
production of FGF-2 and VEGF-A, cell cycle progression and
angiogenesis, and in malignant tumors, high PTTG levels
correlate with tumor invasiveness and serve as a marker of poor
prognosis (reviewed in [26]). Thus, the cellular environment
appears to determine end-point effects of these proteins.
Our hypothesis is outlined in Figure 10. Human gonadotroph
tumors express both FOXL2 and PTTG. The results shown here
indicate that FOXL2 directly activates the clusterin promoter,
while PTTG triggers clusterin via C/EBPs. Both C/EBPs and
clusterin are also induced by DNA damage (data not shown and
[59]). High clusterin, in turn, provokes p15, p16 and p27
expression in vivo and cell-specifically in vitro thus restraining
gonadotroph cell proliferation. These observations point to the
existence of intrinsic lineage-specific pathways restricting pitui-
tary cell cycle progression. Activation of these pathways should be
considered as a contributing factor underlying the overwhelm-
ingly benign nature of pituitary adenomas, enabling maintenance
of vital pituitary homeostatic and metabolic functions, while
protecting the hormone-secreting gland from destruction by
malignancy.
Figure 8. Clusterin attenuation promotes proliferation. Western blot analysis of Cdk inhibitors and proliferation markers A)i nL bT2 cells, B)i n
aT3 cells; C) Percentage of BrdU positive cells 48 h after transfection with siClu. D) Upper panel, Western blot confirms p15 down-regulation, Lower
panel, Percentage of BrdU positive LbT2 cells 48 h after transfection with sip15. E) Upper panel, Western blot confirms p16 down-regulation, Lower
panel, Percentage of BrdU positive LbT2 cells 48 h after transfection with sip16. For BrdU detection, cells were fixed, stained with BrdU antibody and
one thousand cells/field in three randomly chosen fields counted. *, p,0.05.
doi:10.1371/journal.pone.0017924.g008
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Human tissue samples
Pituitary tumors were freshly collected at transsphenoidal
surgery according to an approved Cedars Sinai and Mayo Clinic
Institutional Review Board protocols. Written informed consent
were obtained from all participants. Samples were formalin-fixed
and paraffin-embedded for immunohistochemistry. Diagnosis of
individual tumors was established on the basis of clinical features,
histology, and pituitary hormone immunohistochemistry. Non-
functioning tumors exhibiting gonadotroph-cell markers, including
alpha-glycoprotein subunit (aGSU), LH or FSH were selected for
study. Normal anterior pituitary tissue controls were freshly
obtained at surgery.
Animals
Experiments were approved by the Cedars Sinai Institutional
AnimalCareandUseCommittee(protocol#2683).MiceinaB6C3
genetic background harboring the aGSU-PTTG1-IRES-eGFP
(aGSU.PTTG) transgene were previously described [28]. To obtain
WT and aGSU.PTTG mice from the same breeding, we crossbred
aGSU.PTTG
+/2 males and females, and genotyped by PCR.
BrdU incorporation in vivo
Mice were injected i.p. with BrdU (50 mg/g BW, Sigma-
Aldrich, St Louis, MO) three times at 3 hour intervals, sacrificed
24 h after the first injection and pituitary sections stained (5-BrdU
Labeling and Detection Kit, Roche, Palo Alto, CA). Three
randomly chosen visual fields (1000 cells/per field) were counted,
and three sections/per animal were derived from three of each
genotype analyzed.
SA-b-galactosidase activity
Senescence-associated (SA)-b-galactosidase enzymatic activity
was detected in pituitary cryosections (10 mm) using a b-
galactosidase staining kit (Senescence Cell Staining Kit, Sigma-
Aldrich). Only senescent cells stain at pH 6.0. SA-b-galactosidase
activity in vitro was assayed in 6-well plates in triplicate [29]. Three
randomly chosen visual fields/per well were identified, and 1000
cells/per field counted.
Protein analysis
Pituitary tissues or cells were processed (Immunoprecipitation
Kit, Roche Diagnostics, Indianapolis, IN) for Western blot
analysis, proteins separated by SDS-PAGE, electroblotted onto
Millipore membranes (Millipore, Temecula, CA), and incubated
overnight with antibodies, followed by corresponding secondary
antibodies (Sigma-Aldrich, St. Louis, MO). Antibodies purchased
from Santa Cruz (CA): PCNA, E2F1; and MSH2, MLH1, Rad51,
p27, p16, Clu. PTTG, Ki67, p53, C/EBPb, C/EBPd were
obtained from Abcam (Cambridge, MA). We also used antibodies
to p15 (Biosource); phosphoHistone 3 (ser10) (Cell Signaling
Figure 9. FOXL2 stimulates the clusterin promoter. A) Effects of FOXL2 on the clusterin promoter in aT3 cells 24 h after transfection. Cells were
co-transfected with 200 ng murine pGL3-luc-mClu reporter plasmid and indicated amounts of pcDNA3-His-mFoxl2. The ratio of luciferase to co-
trasfected b-galactosidase control reporter vector was normalized to pCDNA3-null expression vector. SEM was calculated from triplicate assays, and
experiments repeated three times with similar results. Results of a representative experiment are shown; **,p,0.01; B) Western blot analysis of
clusterin expression in aT3 cells 24 hours after transfection with pcDNA3-His-mFoxl2; C) ChiP assay was performed in nuclear fractions derived from
aT3 cell lysates. Top, schematic of the approximate location of primers used in the PCR reactions. Enrichment of specific clusterin promoter
sequences was obtained with primer Set 2. FOXL2, specific antibody, IgG, nonspecific antibody, PCP, positive control primers. The experiment was
repeated twice, and results of a representative assay shown.
doi:10.1371/journal.pone.0017924.g009
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MO).
For immunofluorescence analysis of human tissue we used
antibodies to cH2A.X (ser139), CLU and H3-K9M antibody, all
from Millipore (Billerica, MA); phosphoATM (ser1981, Upstate
Biotech (Millipore); p15, p16, all from Abcam; and p21 (Cell
Signaling) antibodies followed by corresponding secondary
antibodies conjugated with Alexa 488 or with Alexa 568
fluorescent dye (both Molecular Probe, Carlsbad, California).
Antigen retrieval was performed in 10 mM sodium citrate, and
control reactions were devoid of primary antibodies or stained
with blocking antibodies. Samples were imaged with a Leica
TCS/SP spectral confocal scanner (Leica Microsystems, Mann-
heim, Germany) in dual emission mode to distinguish autofluo-
rescence from specific staining.
Human pituitary adenoma PTTG was detected by immuno-
histochemistry with the same antibodies as for Western blot, and
using an avidin-biotin-peroxidase kit (Vector Laboratories,
Burlingame, CA).
Cells, constructs, plasmids and transfections
Mouse pituitary gonadotroph LbT2 and aT3 cell lines were
generously provided by Dr. Pamela Mellon (UC San Diego).
These cells, immortalized with SV40 T-antigen [64], are the only
functional gonadotroph cell lines available.
Murine testis mRNA was used as a source for Pttg1. Primers
were designed as follows: forward, GGAATTCCATGGC-
TACTCTTATCTT, reverse CGGGATCCCCGAATATCTG-
CATCGT. The Expand High Fidelity PCR system (Roche
Diagnostics) was used for amplification reactions. PCR products
were double digested (EcoR1/BamH1), purified and ligated (DNA
ligation Kit, Takara Bio, Japan) into pIRES2-ZsGreen1 vector
(Clontech, Mountain View, CA) to generate cells that co-express
Pttg and a ZsGreen tag.
Mouse clusterin expressing plasmids were amplified from
pCMv6-mClu (Origene, Rockville, MD) by using TaKaRa LA
Taq (Takara), and cloned into the pIRES2-ZsGreen1 vector
(Clontech). The following primers were used for PCR: clusterin
forward: 59 CGGAATTCATGAAGATTCTCCTGCTGTGCG
T3 9; reverse: 59 CGG GAT CCTCATTCCGCACGGC-
TTTTCCT 39.
Mouse clusterin promoter fragment (21855 to +169) was
amplified from mouse genomic DNA using TaKaRa LA Taq,
inserted into the pGL3-Basic luciferase reporter vector (Promega,
San Luis Obispo, CA) and the following primers used for PCR:
forward 59 GGG GTA CCA CAT TCC TCC AAG TTT CTG
39, and reverse 59 CGG GAT CCA TGG GCT CTA GTC ACC
TC 39.
LbT2 and aT3 cells were stably transfected with mPttg-pIRES2-
ZsGreen1 or with mClu-pIRES2-ZsGreen1 to create LbT2mPttg cells
or aT3mClu cells respectively, or with pZsGreen1-N1 alone
(vector). Cells were grown in the presence of 400 mg/ml geneticin
(Invitrogen, Carlsbad, CA). Fourth- and fifth-generation enriched
stable LbT2mPttg or aT3mClu or vector cells were used for
experiments.
Short hairpin RNA expressing vector targeting murine clusterin
shClu-pGFP-V-RS (shClu) were purchased from OriGene( Rock-
villle, MD). Small interfering RNAs targeting murine clusterin,
p15 and p16 (siClu, 1 and 2; sip15, 1 and 2; sip16, 1 and 2) and
scrambled siRNAs as negative controls are from Ambion (Foster
Figure 10. Proliferation restricting pathways in the pituitary gonadotroph cell lineage. FOXL2 directly activates the clusterin promoter,
while Pttg overexpression results in proliferation, DNA damage and stimulation of C/EBPb and d; C/EBPs activate the clusterin promoter. High levels of
secretory clusterin trigger expression of Cdk inhibitors p15, p16 and p27, and C/EBPb also cooperates to induce p15. Up-regulated tumor suppressor
proteins likely underlie proliferation restraint preventing uncontrolled growth of benign pituitary adenomas of gonadotroph cell origin.
doi:10.1371/journal.pone.0017924.g010
Lineage-Specific Restrain of Pituitary Adenomas
PLoS ONE | www.plosone.org 11 March 2011 | Volume 6 | Issue 3 | e17924City, CA). Small interfering RNAs targeting murine C/EBPb,C /
EBPd and scrambled siRNA are from Qiagen (Valencia, CA).
Murine pcDNA3.1(2)C/EBPb was from Addgene (plas-
mid12557), and murine pcDNA3 C/EBPd was a generous gift
from Dr. Koeffler (Cedars Sinai Medical Center). As fetal bovine
serum contains clusterin, cell transfections with mClu,s h Clu and
siClu were conducted in 0.5% fetal bovine serum (FBS).
Transfections were performed using Lipofectamine 2000 (Invi-
trogen,Carlsbad, CA).
pcDNA3-His-mFoxl2 overexpressing plasmid was a generous
gift from Dr. Wei-Hsiung Yang (Mercer University School of
Medicine, Savannah, GA) with the permission of Dr. Buffy S.
Ellsworth (Southern Illinois University School of Medicine,
Carbondale,IL).
Luciferase Assays
LbT2 and aT3 cells were transfected with 800 ng pGL3-luc
basic vector or pGL3-luc-mClu reporter plasmid and co-transfect-
ed with pcDNA3 or pcDNA3 encoding murine C/EBPb or d in
12-well plates. Twenty four later cells were harvested and
monitored for luciferase activity (Promega, Madison, WI). Light
emission was evaluated by luminometer, and normalized to a b-
galactosidase luciferase reference plasmid.
Chromatin Immunoprecipitation Assay (ChiP)
ChiP was performed (Chip-IT Express kit, Active Motif,
Carlsbad, CA) using aT3 pituitary gonadotroph cells which
exhibit abundant clusterin expression. Cells were cross-linked with
formaldehyde, harvested, sonicated, nuclear fraction isolated, and
chromatin immunoprecipitation performed with polyclonal
FOXL2 antibody (Abcam) as well as non-specific mouse IgG.
DNA released from precipitated complexes was amplified by PCR
with 3 pairs of specific primers spanning 1855 nucleotides
upstream from the murine clusterin transcription start site. Primer
set 1 (+169–700): F 59CTTTCCTACCCCAGCGCCGC-39,R 59-
ACCCTGCGCAGCTTTCCACC-39; Primer set 2 (2700–1399):
F5 9-GGACAGCAGAGGCCTTCGGGA-39,R 59-GGGCTG-
CTTGCTGGTCCCTTG-39; Primer set 3 (21400–1855): F 59-
AGGCCCAAGGGCAGAGTGGT-39,R5 9-ACACAGTTTG-
GGTGGCAGGCC-39. PCR products were resolved in 1%
agarose gel and visualized by ethidium bromide.
Apoptosis
The rate of apoptosis was assessed in vitro using the In Situ Cell
Death Detection Kit, AP (TUNEL assay, Roche Diagnostics,
Indianapolis, IN). Three randomly chosen visual fields, each
containing 1000 cells were counted.
Cell proliferation assay
Asynchronized cells were pulsed with 10 mM BrdU (Sigma, St
Louis, Missouri) in phosphate buffered saline for 30 min at 37uC.
Cells were washed, harvested, fixed in 75% ethanol/50 mM
glycin at pH 2.0 and analyzed by FACScan (Becton Dickinson,
Mountain View, California). Experiments were performed in
triplicate. In separate experiments aT3mClu or aT3vector cells
were synchronized in 0.1% FBS for 18 hours, and then
stimulated by addition of 10% FBS. At the indicated times,
duplicate samples were pulsed with BrdU for 30 min, analyzed by
flow cytometry, and S-phase cells identified by staining with
BrdU antibodies.
Statistics
Clusterin and p15 protein expression were compared between
human GH/PRL- and gonadotroph cell pituitary tumors using
Wilcoxon Rank Sum Test. Cellular labeling indices were
analyzed using ANOVA followed by non-parametric t-test
(Mann-Whitney) or Student t-test. Probability of p,0.05 was
considered significant.
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